Special Issue

Novel Heterocyclic Compounds as Potential Anti-Inflammatory and/or Anticancer Agents

Message from the Guest Editors

Heterocyclic compounds have been extensively studied over the years, revealing a broad spectrum of biological activities, including anticancer, antimicrobial, and antiinflammatory effects. This has led to the development of the concept of "Privileged Scaffolds", which refers to chemical structures capable of binding to multiple biological targets with high affinity, achieving selectivity through strategic functional modifications. Thanks to their favorable pharmacological profiles, these scaffolds are widely employed in the rational design of therapeutics and are present in numerous clinically approved anticancer and/or anti-inflammatory agents. The aim of this Special Issue is to provide an up-to-date overview of recent advances in the application of privileged heterocyclic scaffolds in the development of targeted anticancer and/or anti-inflammatory drugs. Original research articles and review papers addressing either the anticancer potential or the anti-inflammatory activity of selective molecular scaffolds are warmly invited.

Guest Editors

Dr. Ester Colarusso

Department of Pharmacy, University of Salerno, Fisciano, Italy

Dr. Assunta Giordano

Istituto di Chimica Biomolecolare-CNR, Via Campi Flegrei, 34, 80078 Pozzuoli, Italy

Deadline for manuscript submissions

31 December 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/242140

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

